Dr. Bernhard Hampl joins ChemWerth Board of Directors
Advertisement
Peter Werth, the President and CEO of US-based ChemWerth Inc, announced that Dr. Bernhard Hampl has joined the company’s board of directors.
Dr. Hampl, received his Ph.D. in pharmaceutical chemistry from Ludwig-Maximillians University in Munich and his career has included working for Cyanamid GmbH where he served as the company's director of research and development and technical director; Chief Executive Officer of Eon Labs; and, President and CEO of Sandoz U.S. While CEO of Sandoz, Dr. Hampl also served as a member of the Executive Board of the Generic Pharmaceutical Association, especially advocating a pathway to the approval and future use of bio-generics.
Most read news
Other news from the department people
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Malonyl-CoA
Category:Basic_amino_acids
CMC Acquires Former ICOS Biologics Operation in Bothell, Washington State, USA - CMC Biopharmaceuticals to purchase facility from Lilly; will retain existing employees
Chondroitin_sulfate
Category:Salts
HLA-B
SYGNIS' AX200 shows efficacy in stroke patients - Phase IIa results exceed expectations